Biotie Therapies - Corporate Action

Biotie signs an LP market making agreement with Nordea

BIOTIE THERAPIES CORP.     STOCK EXCHANGE RELEASE  September 22, 2009
at 10 a.m.

Biotie signs an LP market making agreement with Nordea

Biotie Therapies ("Biotie") and Nordea Bank Finland Plc ("Nordea")
have concluded a market making agreement, which fulfils the
requirements of NASDAQ OMX Helsinki Ltd's Liquidity Providing (LP)
operations. The market making agreement aims at increasing the
share's liquidity and decreasing the share price volatility thus
facilitating trading.

According to the agreement, Nordea will provide Biotie's share with
bids and offers so that the maximum spread is 4% calculated from the
bid quotation. Bids or offers include at least 4,000 shares and the
value of the shares must correspond to at least 4,000 euros.

Nordea undertakes to submit bids and offers for Biotie's share on the
official list in the trading system of NASDAQ OMX Helsinki on each
trading day for at least 85 per cent of the time of continuous
trading, at the opening and closing call of the trading day and in
the auction procedures applicable to the share during a trading day.

The market making in accordance with the agreement will begin on
September 24, 2009. After a 6-month term, the market making agreement
is valid until further notice. The term of notice of the agreement is
one month.



Turku, September 22, 2009

Biotie Therapies Corp.


Timo Veromaa
President and CEO

For further information, please contact:

Virve Nurmi, Investor Relations Manager
tel. +358 2 274 8911, e-mail: virve.nurmi@biotie.com

www.biotie.com

Distribution:
NASDAQ OMX Helsinki Ltd
Main Media
www.biotie.com

Biotie Therapies Corp.
Biotie is a drug discovery and development company focused on central
nervous system and inflammatory diseases. It has a broad range of
innovative small molecule and biological drug candidates at different
stages of clinical and pre-clinical development. Biotie's products
address diseases with high unmet medical need and significant market
potential, including addiction and psychotic disorders, rheumatoid
arthritis, psoriasis and chronic obstructive pulmonary disease
(COPD). The most advanced product, nalmefene for alcohol dependence,
is currently in phase III clinical development by licensing partner
H. Lundbeck A/S.

The commercial value of the pipeline has been demonstrated through
existing alliances with top-tier global pharmaceutical companies such
as Lundbeck, Roche and Wyeth. Biotie has operations in Turku, Finland
and Radebeul, Germany.

Biotie shares are listed on NASDAQ OMX Helsinki Ltd.